In conclusion, our findings provide insight into the miR-28-5p/IGF-1 axis as a potential therapeutic target against liver CSCs and a potential predictor for sorafenib treatment of HCC patients. This evidence concerns the gene IGF1 and hepatocellular carcinoma.